TrialClinical cancer research : an official journal of the American Association for Cancer Research2017

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Bojana Jovanović et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.